Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LGVN | 3 | neutral | 2/10 | Two new insiders (Leah Rush Cann and Deborah Ascheim) filed initial beneficial ownership statements on Form 3, each repo | Jul 13, 2026 |
| BIIB | PRESS-RELEASE | bullish | 6/10 | FDA approved Biogen's sBLA for LEQEMBI IQLIK, a once-weekly subcutaneous injection initiation dose for early Alzheimer's | Jul 13, 2026 |
| HYEX | 8-K | neutral | 2/10 | Chief Brand Officer Aaron Hefter resigned on July 7, 2026, with no replacement named and the position left vacant. The f | Jul 13, 2026 |
| AAPG | 6-K | neutral | 1/10 | Ascentage Pharma Group International filed a 6-K furnishing an administrative correction to the date of the annual gener | Jul 13, 2026 |
| GYRE | S-3/A | neutral | 3/10 | Gyre Therapeutics filed Pre-Effective Amendment No. 1 to its S-3 shelf registration, registering 31,302,863 shares of co | Jul 13, 2026 |
| ERAS | PRESS-RELEASE | bullish | 7/10 | Erasca reported encouraging preliminary Phase 1 data for ERAS-0015, its pan-RAS molecular glue, showing a 57% unconfirme | Jul 13, 2026 |
| EVO | PRESS-RELEASE | bearish | 8/10 | Evotec SE reported preliminary Q2 2026 results with EPS of -€0.69, a massive miss vs the €0.09 consensus (-911.8% surpri | Jul 13, 2026 |
| MEHA | 25-NSE | bearish | 8/10 | Nasdaq has finalized the delisting of Functional Brands Inc. (MEHA) common stock, effective at the open on July 23, 2026 | Jul 13, 2026 |
| SHPH | 3 | neutral | 2/10 | HRT Financial LP filed a Form 3 initial statement of beneficial ownership, disclosing direct ownership of 60,540 shares | Jul 13, 2026 |
| CERO | 25-NSE | bearish | 7/10 | Nasdaq has filed a Form 25-NSE to formally remove CERO Therapeutics' securities from listing and registration, effective | Jul 13, 2026 |
| STLN | INSIDER-BUY | neutral | 3/10 | Jorey Chernett, a 10% owner of Oncology Institute, purchased $88K worth of TOI shares on the open market at $5.85/share | Jul 13, 2026 |
| GSK | 6-K | neutral | 1/10 | GSK filed a routine 6-K reporting PDMR share acquisitions under the company's Share Reward Plan and dividend reinvestmen | Jul 13, 2026 |
| CPIX | PRESS-RELEASE | bullish | 7/10 | Cumberland Pharmaceuticals declared a special dividend of $1.50 per share and authorized a $5M buyback, returning capita | Jul 13, 2026 |
| SPRC | 3/A | neutral | 2/10 | Itschak Shrem filed an amended Form 3 (3/A) to correct the footnote disclosure regarding his beneficial ownership of Sci | Jul 13, 2026 |
| TNXP | 8-K | bullish | 6/10 | Tonix announced a major Medicare Part D payer agreement for TONMYA, adding approximately 9 million Medicare lives (16% o | Jul 13, 2026 |
| QTTB | 8-K | bullish | 7/10 | Q32 Bio reported positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a trial of bempikibart in alopecia | Jul 13, 2026 |
| KMDA | 6-K | neutral | 3/10 | Kamada announced positive results from an investigator-initiated study of CYTOGAM presented at the 2026 ISHLT annual mee | Jul 13, 2026 |
| ENLV | 6-K | bullish | 7/10 | Enlivex announced FDA Regenerative Medicine Advanced Therapy (RMAT) designation for Allocetra in age-related knee osteoa | Jul 13, 2026 |
| OABIW | 8-K | neutral | 3/10 | OmniAb appointed Amechi Nwachuku as Chief Operating Officer effective July 13, 2026. The appointment is a routine additi | Jul 13, 2026 |
| MTNB | 425 | bearish | 7/10 | Matinas BioPharma (MTNB) has filed a definitive business combination agreement with GH Power Inc., a clean-energy compan | Jul 13, 2026 |
| OCGN | 8-K | bullish | 6/10 | Ocugen signed a binding term sheet with Roots Pharmaceutical to license OCU400 modifier gene therapy for retinitis pigme | Jul 13, 2026 |
| QTTB | 8-K | bullish | 7/10 | Q32 Bio announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a trial for bempikibart in severe | Jul 13, 2026 |
| VYGR | 8-K | bullish | 6/10 | Voyager Therapeutics presented favorable GLP toxicology data for VY1706, its tau-silencing gene therapy for Alzheimer's | Jul 13, 2026 |
| DARE | 8-K | neutral | 2/10 | Dare Bioscience filed an 8-K to furnish a corporate investor presentation dated July 13, 2026, as Exhibit 99.1. The docu | Jul 13, 2026 |
| ONCY | 8-K | neutral | 4/10 | Oncolytics Biotech provided a clinical and regulatory update on its REO 033 study in RAS-mutant MSS colorectal cancer, r | Jul 13, 2026 |
| SLXN | DEFA14A | neutral | 3/10 | Silexion Therapeutics adjourned its extraordinary general meeting to July 20, 2026, without conducting business. The mee | Jul 13, 2026 |
| ESPR | 25-NSE | bullish | 7/10 | Esperion Therapeutics has been delisted from Nasdaq following its acquisition by ArchiMed (via Essence Parent Inc.) for | Jul 13, 2026 |
| NVO | 6-K | neutral | 2/10 | Novo Nordisk filed a routine 6-K providing a weekly update on its ongoing DKK 15 billion share repurchase program. There | Jul 13, 2026 |
| ESPR | 8-K | bullish | 7/10 | Esperion Therapeutics completed its acquisition by ArchiMed (via Essence Parent Inc.) on July 13, 2026, for $3.16 per sh | Jul 13, 2026 |
| ARTL | PRESS-RELEASE | neutral | 4/10 | Artelo Biosciences announced nonclinical results showing ART27.13 reduced neuropathic pain behaviors in a paclitaxel-ind | Jul 13, 2026 |